Giannini E H, Brewer E J, Person D A, He X H
J Rheumatol. 1986 Aug;13(4):768-70.
Auranofin (AF, Ridaura) was administered to 23 children with juvenile rheumatoid arthritis during a prospective, open labelled, noncontrolled trial designed to establish longterm safety and preliminary efficacy. Dosages of AF were up to 0.2 mg/kg/day, with either aspirin (60-80 mg/kg/day), naproxen (400-600 mg/m2/day), or tolmetin sodium (20-40 mg/kg/day) serving as the concurrent nonsteroidal antiinflammatory drug. Nearly all patients showed an initial favorable response, however tachyphylaxis occurred in one-third (mean duration of therapy prior to the development of inefficacy = 22.6 mo). Clinical remission was observed in 6 patients an average of 15 months after enrollment. The drug appears to be safe for extended periods; 7 children are continuing AF at the present time with a mean duration of therapy of 4.25 years (maximum followup = 4.6 years).
在一项旨在确定长期安全性和初步疗效的前瞻性、开放标签、非对照试验中，对23名幼年类风湿性关节炎儿童使用了金诺芬（AF，商品名：立达罗）。AF的剂量高达0.2毫克/千克/天，同时使用阿司匹林（60 - 80毫克/千克/天）、萘普生（400 - 600毫克/平方米/天）或托美丁钠（20 - 40毫克/千克/天）作为非甾体抗炎药。几乎所有患者最初都有良好反应，但三分之一的患者出现快速耐受（无效前的平均治疗持续时间 = 22.6个月）。6名患者在入组后平均15个月出现临床缓解。该药物长期使用似乎是安全的；目前有7名儿童继续使用AF，平均治疗持续时间为4.25年（最长随访 = 4.6年）。
